BSETitan Biotech LtdMinimalNeutral
Announced Mon, 4 May · 12:25 IST

Annual Secretarial Compliance Report for the financial year ending March 31, 2026

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.7%1-day move
₹495.00
prior close
₹504.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.6-1.4-1.3-1.3-1.7-4.7-5.7-5.9-6.7-6.5-4.5-10.5-17.5
Up moveDown movePending
AI summary

Titan Biotech Ltd has filed its Annual Secretarial Compliance Report for FY 2025-26, as mandated under SEBI Regulation 24A. The report, issued by Practicing Company Secretary Amit Anand on April 24, 2026, confirms that the company maintained full compliance with all SEBI regulations throughout the review period. No deviations or violations were reported across all checked items including SEBI LODR, Takeover Regulations, Insider Trading Regulations, and secretarial standards. The auditor verified compliance with related party transactions, website disclosures, document preservation, and performance evaluation requirements. No actions were taken by SEBI or stock exchanges against the company, its promoters, or directors during the period. This clean report was submitted to BSE on May 4, 2026.

Likely market impact

This clean compliance report indicates strong governance practices with no regulatory issues. Shareholders can view this positively as the company has maintained full adherence to SEBI requirements without any penalties or show cause notices.